Evelo Biosciences, Inc., a biotechnology company, focuses on the development of monocolonal microbials for the treatment of inflammatory diseases and cancer.
+ 1 more risk
Adequate balance sheet and overvalued.
Share Price & News
How has Evelo Biosciences's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: EVLO's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: EVLO underperformed the US Biotechs industry which returned 24.5% over the past year.
Return vs Market: EVLO underperformed the US Market which returned 12.5% over the past year.
Price Volatility Vs. Market
How volatile is Evelo Biosciences's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 months ago | Simply Wall StDo Institutions Own Evelo Biosciences, Inc. (NASDAQ:EVLO) Shares?
5 months ago | Simply Wall StCould The Evelo Biosciences, Inc. (NASDAQ:EVLO) Ownership Structure Tell Us Something Useful?
1 year ago | Simply Wall StCan We See Significant Institutional Ownership On The Evelo Biosciences Inc (NASDAQ:EVLO) Share Register?
Is Evelo Biosciences undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate EVLO's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate EVLO's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: EVLO is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: EVLO is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate EVLO's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: EVLO is good value based on its PB Ratio (2.5x) compared to the US Biotechs industry average (3.3x).
How is Evelo Biosciences forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: EVLO is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: EVLO is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: EVLO is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: Insufficient data to determine if EVLO's revenue is forecast to grow faster than the US market.
High Growth Revenue: Insufficient data to determine if EVLO's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: EVLO is forecast to be unprofitable in 3 years.
How has Evelo Biosciences performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: EVLO is currently unprofitable.
Growing Profit Margin: EVLO is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: EVLO is unprofitable, and losses have increased over the past 5 years at a rate of 37% per year.
Accelerating Growth: Unable to compare EVLO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: EVLO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-22.5%).
Return on Equity
High ROE: EVLO has a negative Return on Equity (-127.05%), as it is currently unprofitable.
How is Evelo Biosciences's financial position?
Financial Position Analysis
Short Term Liabilities: EVLO's short term assets ($92.7M) exceed its short term liabilities ($13.6M).
Long Term Liabilities: EVLO's short term assets ($92.7M) exceed its long term liabilities ($31.1M).
Debt to Equity History and Analysis
Debt Level: EVLO's debt to equity ratio (28.6%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if EVLO's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: EVLO has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: EVLO has less than a year of cash runway if free cash flow continues to reduce at historical rates of 40.6% each year
What is Evelo Biosciences's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate EVLO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate EVLO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if EVLO's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if EVLO's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of EVLO's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Simba Gill (55 yo)
Dr. Balkrishan Gill, also known as Simba, Ph.D. served as Independent Non-Executive Director of Realm Therapeutics plc since 2019 until July 31, 2019. He serves as Executive Chair and Chief Executive Offic ...
CEO Compensation Analysis
Compensation vs Market: Simba's total compensation ($USD2.80M) is above average for companies of similar size in the US market ($USD1.34M).
Compensation vs Earnings: Simba's compensation has been consistent with company performance over the past year.
|Chief Scientific Officer and President of Research & Development||4.33yrs||US$1.49m||0.40% |
|Controller & Principal Accounting Officer||0.50yr||no data||0.0065% |
|Head of Technical Operations||0.50yr||no data||no data|
|Head of Investor Relations||no data||no data||no data|
|General Counsel & Secretary||1.83yrs||no data||no data|
|VP & Head of Communications||no data||no data||no data|
|Head of Research||0.50yr||no data||no data|
|Chief Medical Officer||2.5yrs||US$2.29m||no data|
|Global Head of Regulatory Affairs & EU Head of Clinical Development||0.50yr||no data||no data|
|Chief Development Officer||0.33yr||no data||no data|
Experienced Management: EVLO's management team is not considered experienced ( 0.5 years average tenure), which suggests a new team.
|Independent Director||4.17yrs||US$110.86k||no data|
|Independent Director||3.5yrs||US$129.70k||no data|
|Independent Chairman||0.92yr||US$1.02m||no data|
|Independent Director||2.33yrs||US$114.67k||no data|
|Independent Director||2.5yrs||US$114.67k||no data|
Experienced Board: EVLO's board of directors are not considered experienced ( 2.5 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 44%.
Evelo Biosciences, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Evelo Biosciences, Inc.
- Ticker: EVLO
- Exchange: NasdaqGS
- Founded: 2014
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$175.781m
- Shares outstanding: 46.14m
- Website: https://www.evelobio.com
Number of Employees
- Evelo Biosciences, Inc.
- 620 Memorial Drive
- Suite 200 West
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|EVLO||NasdaqGS (Nasdaq Global Select)||Yes||Common Stock||US||USD||May 2018|
Evelo Biosciences, Inc., a biotechnology company, focuses on the development of monocolonal microbials for the treatment of inflammatory diseases and cancer. It is involved in developing EDP1066 and EDP181 ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/08/03 00:15|
|End of Day Share Price||2020/07/31 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.